Vagus Nerve Stimulation for Depression: What to Know About Treatment-Resistant Depression

ZenoWellTeam

When depression has continued through medication changes, therapy, and other advanced treatments, it is reasonable to start asking what comes next. That is usually the context behind searches for vagus nerve stimulation for depression.

VNS may help some people with highly treatment-resistant depression, but the best-established pathway is very specific: an implanted medical device used as a long-term add-on treatment under specialist care. That is different from non-invasive research devices, ear-worn wellness products, or general “vagus nerve” techniques.

Can Vagus Nerve Stimulation Help Depression?

Yes, for some people with treatment-resistant depression. Implanted VNS is generally considered after multiple adequate depression treatments have not provided enough benefit.
The FDA-approved use is narrow. The FDA indication for the VNS Therapy System covers adults 18 or older with chronic or recurrent depression who are currently experiencing a major depressive episode and have not responded adequately to four or more adequate antidepressant treatments.
VNS is an add-on treatment. It is approved as adjunctive long-term therapy, so psychiatric treatment continues rather than ending after implantation.
It is slow. Implanted VNS is not designed for rapid mood improvement. Benefit may build over months, and some patients do not respond.
Implanted VNS and ear-worn VNS are not interchangeable. Depression evidence from an implanted cervical VNS system does not automatically apply to taVNS or consumer wellness devices.
VNS is not an emergency treatment. Suicidal thoughts, self-harm risk, mania, psychosis, or an inability to stay safe require immediate professional care.

Think of VNS therapy for depression as a specialist-guided option for unusually difficult cases, not a quick mood-boosting device.

Why VNS Is Considered for Treatment-Resistant Depression

Treatment-Resistant Depression Is Different From Everyday Low Mood

Major depression can affect sleep, appetite, energy, motivation, concentration, relationships, and the ability to work or manage ordinary life. In treatment-resistant depression, the problem is not simply that symptoms are severe. It is that adequate treatments have repeatedly failed to produce enough improvement.

There is no single treatment-resistance threshold used in every study or clinical setting. That matters here because the FDA indication for implanted VNS is more demanding than many everyday uses of the term TRD: it requires an inadequate response to four or more adequate antidepressant treatments.

So VNS for depression is mainly a treatment-resistant depression question. It is not a general strategy for a difficult week, temporary low mood, or stress.

VNS Uses a Body-to-Brain Signal Pathway

Implanted VNS places a pulse generator under the skin of the chest and connects it by a lead to the left vagus nerve in the neck. The device sends repeated electrical signals through that nerve toward the brain. Those signals can influence networks involved in mood and other functions, although exactly how VNS produces antidepressant effects is still being studied.

It is more useful to think of VNS as repeated neuromodulation than as a device that simply “raises” or “lowers” one brain chemical.

VNS Is Long-Term Neuromodulation, Not a Quick Mood Switch

This difference in timing is central to understanding VNS. Some advanced depression treatments are chosen partly because clinicians need a response relatively quickly. Implanted VNS sits at the other end of that spectrum.

Benefits may take several months to become noticeable, and the treatment is intended to continue over the long term. That slow time course becomes important when comparing VNS with ECT, TMS, or esketamine—and when deciding how long a fair trial of VNS should last.

Who May Qualify for Implanted VNS?

The FDA-Approved Use Is Specific

The phrase FDA-approved VNS for depression can sound broader than it really is.

The FDA-approved indication for the implanted VNS Therapy System is adjunctive long-term treatment of chronic or recurrent depression in people who:

Are 18 years of age or older.
Are currently experiencing a major depressive episode.
Have chronic or recurrent depression.
Have not had an adequate response to four or more adequate antidepressant treatments.

That is not the same as saying anyone who has been told they have treatment-resistant depression automatically qualifies for a vagus nerve stimulator for depression. A psychiatrist still needs to review the diagnosis, treatment history, current severity, medical risks, and whether an implanted long-term therapy makes sense.

Difficult-to-Treat Depression vs. Treatment-Resistant Depression

You may also see the phrase difficult-to-treat depression. It is useful patient-friendly language because real depression care is more complicated than simply counting failed medications. But it is not automatically identical to the regulatory criteria for implanted VNS.

For this article, treatment-resistant depression is the more precise term when discussing FDA eligibility and clinical trials. The actual treatment history matters more than the label.

Who May Not Be an Immediate Can didate?

Implanted VNS is unlikely to be the immediate next step when someone needs rapid psychiatric stabilization, cannot safely undergo the procedure, or expects a fast antidepressant effect. Acute suicidal risk, psychosis, severe mania, or an inability to care for oneself changes the priority from long-term neuromodulation to immediate safety and treatment.

Candidacy is therefore about more than how bad the depression feels today. It depends on what has already been tried, how urgent the situation is, and whether the person can realistically commit to surgery, programming, and long-term follow-up.

How Implanted VNS Therapy Works

A Pacemaker-Like Device Is Implanted in the Chest

For depression, the established medical form of VNS is implanted. A small pulse generator is placed beneath the skin in the upper chest. A lead runs under the skin to the left vagus nerve in the neck, where electrodes deliver programmed stimulation.

The operation does not place electrodes directly inside the brain. The stimulation reaches the brain indirectly through the vagus nerve.

The Device Needs Programming and Follow-Up

The surgery is the beginning of treatment, not the end of it.

After implantation, clinicians program the device and can adjust stimulation over time based on tolerability and the treatment plan. Psychiatric visits continue, and patients may remain on antidepressants or receive other treatments as clinically appropriate.

The implanted generator also has a finite battery life, so long-term planning includes device checks and eventual generator replacement. This makes VNS therapy for treatment-resistant depression a treatment pathway rather than a one-time procedure.

Why It Is Not the Same as Brain Surgery

VNS is sometimes described as “not brain surgery” because no electrode is implanted in brain tissue. That distinction is useful, but it should not make the procedure sound trivial. Implanted VNS still involves surgery in the chest and neck, anesthesia, an implanted lead and generator, and ongoing device management.

What Clinical Evidence Shows About VNS for Depression

Earlier Evidence Suggested Some Long-Term Benefit

One reason implanted VNS remained interesting despite mixed early randomized results was the pattern seen over longer follow-up.

In 2017, Scott Aaronson and colleagues reported a five-year U.S. treatment-resistant depression registry involving 795 people with severe, chronic depression who had failed at least four treatments. The cumulative response rate was 67.6% among patients receiving VNS plus treatment as usual, compared with 40.9% with treatment as usual alone. Cumulative first-time remission was 43.3% versus 25.7%.

Those numbers are notable, but the design matters. This was a prospective open-label, nonrandomized observational registry. Patients were not randomly assigned to VNS, so the results cannot rule out the kinds of group differences and selection effects that a randomized sham-controlled trial is designed to reduce.

The study therefore provided an important long-term signal—not definitive proof that every patient with refractory depression will benefit.

What the RECOVER Trial Adds

RECOVER is more important for current decision-making because it tested implanted VNS in a large randomized, double-blind, sham-controlled design.

The 12-month RECOVER trial enrolled 493 adults with markedly treatment-resistant major depression. Participants had failed at least four adequate antidepressant trials in the current episode. They were randomized to active VNS or implanted VNS with no stimulation, while continuing treatment as usual.

The result was not a simple win or loss.

The study’s primary endpoint measured the percentage of time participants spent in response on the Montgomery-Åsberg Depression Rating Scale, or MADRS, during months 3 through 12. That primary endpoint did not significantly separate active VNS from sham.

However, several secondary measures told a different story. Clinician-rated CGI-I, patient-rated QIDS-SR, and masked clinician-rated QIDS-C outcomes showed antidepressant benefits favoring active stimulation. A separate RECOVER analysis of quality of life and daily function found advantages for active VNS on some quality-of-life and activity-impairment measures, while other measures—including WHODAS and the EQ-5D visual analog score—did not show significant group differences.

RECOVER was neither a clean success nor a clean failure. The prespecified primary MADRS outcome missed, while several other symptom, functioning, and quality-of-life measures favored active VNS. That mixed result is more useful to patients than reducing the study to either “VNS works” or “VNS failed.”

Why VNS May Take Months to Work

The long time course may be one of the most unusual features of vagus nerve stimulation for depression.

A 2026 RECOVER durability report followed 214 participants who continued active adjunctive VNS during a second year. Among people who already had meaningful benefit at 12 months, the median proportion maintaining that level of benefit was about 81% at 24 months across seven measures. More surprisingly, among those who had not reached meaningful benefit at 12 months, a median 37.8% reached it by month 24.

That does not mean everyone should simply wait two years. The second year was an open-label extension, not another year of randomized sham comparison, and treatment decisions still need to be individualized.

What it does show is that VNS has a very different decision timeline from a rapid-acting treatment. A lack of obvious change after a few weeks does not answer the VNS question.

What VNS Does Not Prove

Implanted VNS does not work for everyone, it is not a replacement for ongoing depression care, and even the strongest implanted-VNS studies do not prove that every device stimulating the vagus nerve treats depression.

That last distinction becomes especially important with non-invasive VNS and ear-worn products.

How VNS Compares With Other Advanced Depression Treatments

Once depression has become difficult to treat, the useful question is rarely “Which treatment is best?” The better question is what role each option plays in a particular clinical situation.

VNS vs. TMS

TMS is non-invasive: an external magnetic coil stimulates targeted brain regions over a treatment course. Implanted VNS requires surgery and then provides long-term nerve stimulation from an implanted system.

The National Institute of Mental Health describes rTMS as an FDA-cleared treatment for treatment-resistant depression and VNS as a surgical option used much less commonly. For someone choosing between VNS vs. TMS for depression, invasiveness, prior treatments, access, treatment schedule, and expected time course are more meaningful differences than the fact that both are neuromodulation.

VNS vs. ECT

ECT occupies a different place when depression is extremely severe or a fast response is clinically important. NIMH notes that ECT may be considered in life-threatening situations such as severe suicidality, catatonia, or inability to eat or drink.

VNS is not a rapid rescue treatment. In a VNS vs. ECT depression decision, speed is therefore a fundamental difference. ECT also has its own anesthesia, seizure, cognitive, and maintenance considerations; VNS has surgical and implanted-device considerations. Neither should be presented as universally “better” or “safer.”

VNS vs. Esketamine or Ketamine

Esketamine belongs to a drug-based pathway rather than implanted neuromodulation. It is used under medical supervision for treatment-resistant depression and is associated with monitoring requirements because of risks including sedation and dissociation.

It is also worth separating esketamine from ketamine in general: FDA-approved esketamine is used for psychiatric indications, while racemic ketamine itself is not FDA-approved as a depression treatment.

The main point in a VNS vs. esketamine depression comparison is timing and treatment burden. Esketamine is discussed as a much faster-acting option; VNS is an implanted long-term strategy whose benefit may build slowly.

VNS vs. DBS

Deep brain stimulation places electrodes directly in selected brain regions. VNS stimulates a peripheral nerve and sends signals toward the brain instead.

For depression, that difference is not merely anatomical. NIMH currently describes DBS for treatment-resistant depression as experimental, while implanted VNS has an FDA-approved depression indication. DBS belongs to a much more specialized research pathway.

Cost, Surgery, Insurance, and Long-Term Follow-Up

Surgery and Device Costs

Implanted VNS is not simply the price of a pulse generator. The treatment pathway can include the device, surgeon and facility fees, anesthesia, programming visits, psychiatric follow-up, and eventual generator replacement. Actual out-of-pocket cost varies widely with coverage and health system.

That makes cost structurally different from an outpatient TMS course, a medication copay, or a consumer wellness device.

Insurance Coverage Can Be a Barrier

FDA approval does not automatically mean routine insurance coverage.

Medicare is a good example. CMS currently covers FDA-approved VNS for treatment-resistant depression through Coverage with Evidence Development when treatment is provided within a CMS-approved study meeting the coverage requirements. RECOVER was approved under that pathway. CMS states that VNS for treatment-resistant depression remains non-covered when furnished outside a CMS-approved CED study.

Private insurance is plan-specific. Anyone seriously considering implanted VNS should verify not only whether the device is covered, but also the implantation procedure, programming, follow-up, and future replacement costs.

Long-Term Maintenance Matters

VNS is not a one-and-done surgery. The device needs follow-up, stimulation may be adjusted, battery replacement eventually becomes necessary, and certain medical procedures can require device-specific precautions.

Psychiatric care also continues. That long-term treatment relationship should be part of the decision before implantation, not something discovered afterward.

Implanted VNS vs. Non-Invasive and Ear-Worn VNS Devices

Implanted VNS for Treatment-Resistant Depression

When people read that VNS is FDA-approved for depression, this is the category they are reading about: an implanted system stimulating the left cervical vagus nerve for a specific treatment-resistant population, used as adjunctive long-term treatment.

It does not mean that “vagus nerve stimulation” is one interchangeable device category with one shared depression indication.

Non-Invasive VNS and taVNS for Depression Research

Non-invasive vagus nerve stimulation for depression is an active research area, especially transcutaneous auricular VNS, or taVNS, which delivers stimulation through selected areas of the outer ear.

A 2023 systematic review and meta-analysis of taVNS for depressive disorders included 12 randomized studies and 838 participants. Pooled results favored taVNS on depression scores, but the authors rated important comparisons as low or very low quality because individual subgroups were small and the underlying studies varied.

Research has continued since then, including studies in major depressive disorder. But stimulation sites, devices, parameters, patient populations, control conditions, and treatment schedules still vary. “taVNS is being studied for depression” is therefore not the same statement as “non-invasive VNS is an FDA-approved treatment for depression.” NIMH currently describes transcutaneous VNS for depression as experimental.

Ear-Worn Wellness VNS Devices

Ear-worn taVNS device used for non-invasive vagus nerve stimulation and nervous system support

This is where the user’s goal needs to be clear.

If someone is looking for treatment for major depression, treatment-resistant depression, bipolar depression, or suicidal symptoms, that is a medical question for qualified mental-health professionals. An ear-worn wellness device serves a different purpose. ZenoWell Luna Plus combines taVNS routines for relaxation, meditation, sleep, focus, and recovery with AI-guided support and HRV, sleep, and session insights in the Zeno App. These features can make a daily wellness routine easier to follow and understand, but they do not make Luna Plus a treatment for depression. The evidence for implanted VNS discussed above should not be transferred to an ear-worn consumer device.

Why Device-Specific Evidence Matters

For a depression claim, the evidence should match the device, stimulation site, treatment protocol, patient population, diagnosis, and outcome.

RECOVER studied an implanted cervical VNS system in markedly treatment-resistant major depression. A taVNS study using a research ear electrode answers a different question. A consumer wellness device answers another one again.

Evidence travels much less easily between devices than the phrase “vagus nerve stimulation” makes it sound.

Safety: Who Should Be Careful With VNS for Depression?

Surgery and Device Risks

Implanted VNS has real surgical and device-related risks. NIMH notes complications including infection or pain after implantation, movement or malfunction of the device, and the possibility of additional surgery if a problem needs correction.

This is one reason candidacy is assessed by a medical team rather than decided from symptom severity alone.

Stimulation Side Effects

Commonly discussed stimulation-related effects include voice changes or hoarseness, cough or sore throat, neck discomfort or headache, difficulty swallowing, nausea, tingling, and breathing discomfort—particularly during exertion. Side effects may change as clinicians adjust the stimulation settings.

These are effects of implanted VNS and should not simply be copied onto every non-invasive VNS product.

Mental Health Red Flags That Need Immediate Help

VNS is not an emergency intervention. Thoughts of suicide or self-harm, feeling unable to stay safe, psychosis, hallucinations or delusions, severe mania or agitation, sudden major worsening of depression, or an inability to eat, sleep, or care for yourself require immediate professional or emergency support.

Do not wait for a device consultation or a future neuromodulation appointment when the immediate problem is safety.

Questions to Ask a Psychiatrist or Specialist

Do I meet the clinical and treatment-history criteria for treatment-resistant depression?
Which adequate treatments have I already tried, and were the dose and duration sufficient?
Why are we considering VNS now rather than TMS, ECT, esketamine, medication augmentation, or another option?
Would VNS be added to my current treatment plan?
What improvement would count as a meaningful response for me?
How long would we continue before judging whether VNS is helping?
What surgical and stimulation risks are most relevant to my health?
What does my insurance actually cover?
What happens if the device does not help or causes intolerable side effects?
What is the plan if my depression worsens while we are waiting for a response?

FAQs

Can vagus nerve stimulation help depression?

Implanted VNS may help some adults with highly treatment-resistant depression, but it is generally considered after multiple adequate treatments have not provided enough benefit. It is not a first-line treatment for depression.

Is VNS FDA-approved for depression?

Yes, for a specific implanted system and patient population. The approved use is adjunctive long-term treatment for adults 18 or older with chronic or recurrent depression, a current major depressive episode, and inadequate response to four or more adequate antidepressant treatments.

Who qualifies for VNS for depression?

Eligibility depends on documented treatment resistance, diagnosis, current clinical status, medical and surgical safety, and specialist assessment. Having severe depression alone does not automatically make someone a candidate for implanted VNS.

How long does VNS take to work for depression?

It can take months. VNS is considered a slow, long-term neuromodulation therapy, and RECOVER follow-up data suggest that some meaningful benefits may continue to emerge beyond the first year.

Does VNS replace antidepressants or therapy?

No. The implanted depression indication is adjunctive, meaning VNS is added to ongoing treatment rather than replacing psychiatric medication, psychotherapy, or other clinically appropriate care.

How is VNS different from TMS?

TMS uses external magnetic stimulation and does not require surgery. Implanted VNS uses a generator and lead to stimulate the left vagus nerve over the long term. Their treatment schedules, invasiveness, and patient pathways are different.

Is non-invasive VNS approved for depression?

Research on non-invasive VNS and taVNS for depression is active, but this should not be confused with the FDA-approved implanted VNS indication. Regulatory status must be checked for the exact device and intended use.

Is ZenoWell TaVNS Luna for depression?

No. ZenoWell Luna is an ear-worn wellness device for structured routines such as relaxation, meditation, and sleep preparation. It should not be described as a treatment for major depression, treatment-resistant depression, bipolar depression, or suicidal symptoms.

Who should not use VNS for depression?

Implanted VNS candidacy must be determined by a specialist team. People needing urgent psychiatric stabilization, those with surgical or medical concerns, and anyone with immediate safety risks need appropriate professional assessment rather than self-selecting VNS.